

Wroclaw, August 8, 2025

Genomtec S.A. newsletter

Ladies and Gentlemen,

This newsletter summarizes the most important developments from recent weeks. Among them, you'll find information on changes in the organizational structure, participation in the ADLM conference in Chicago, an interview with the CEO for PAP Biznes, management changes, granting patent protection in Japan, and the results of this year's surveillance audit as part of the ISO13485 certification.

1. Changes in the organizational structure – separation of special purpose vehicles

On July 11, 2025, the Extraordinary General Meeting (EGM) of Genomtec S.A. approved the contribution of tangible and intangible assets related to the Genomtec ID and OncoSNAAT projects to newly established special purpose vehicles: GMT ID S.A. and GMT GENOMICS S.A. Genomtec S.A. holds 100% of the shares in both companies. This change is intended to facilitate the potential sale of individual projects or the acquisition of an external investor for each of them.

CEO Miron Tokarski announced that the reorganization increases flexibility in the M&A process and responds to feedback gathered during the M&A process. The reorganization will also facilitate a smooth commercialization process by allowing partners to invest in each project independently.

Source: <https://genomtec.com/2025/07/14/genomtec-ma-zgode-akcjonariuszy-na-wniesienie-aportem-aktywow-do-spolek-zaleznych-w-celu-przyspieszenia-procesu-sprzedazy-projektow/>

2. Participation in the ADLM conference in Chicago

From July 27-31, 2025, Genomtec representatives, including CEO Miron Tokarski and Chief Research Officer Małgorzata Małodobra-Mazur, attended the ADLM conference in Chicago. It was one of the most important global events in the field of laboratory medicine and diagnostics. The purpose of the visit was to showcase the company's technologies and learn about current scientific, regulatory, and market trends. During the meetings, the team presented the Genomtec ID mobile diagnostic system and other innovative technologies from the company.

This year's ADLM conference demonstrated the growing importance of molecular diagnostics compared to other diagnostic methods as well as the rapid development of companies manufacturing microfluidic systems. The growth of competition in the advanced manufacturing subcontracting sector may lead to price decrease, which in turn will positively impact manufacturers of diagnostic systems.

Source: <https://www.linkedin.com/feed/update/urn:li:activity:7356592727968378881>

3. Interview of the President of the Management Board for PAP Biznes

Miron Tokarski, CEO of Genomtec SA, gave an interview to PAP Biznes, in which he revealed the company's plans. The priority in the commercialization process is the Genomtec ID project due to its technological maturity. The company aims to sell or license Genomtec ID, whereas for OncoSNAAT, it is seeking a strategic partnership that may ultimately lead to a sale. The CEO mentioned that the company continues talks with numerous companies, primarily from the US, and has signed confidentiality agreements.

In the second half of 2025, Genomtec plans to complete work on a new generation of microfluidic cards for the Genomtec ID project and on the technical requirements for the card in the oncology project. The new card is expected to be less expensive to produce and provide faster diagnostic

results, which addresses market needs. The CEO also announced plans to develop a new project leveraging artificial intelligence to accelerate research and development of new genetic tests. The company is counting on funding for this project.

Source: <https://biznes.pap.pl/wiadomosci/gry-i-technologie/genomtec-liczy-na-sprzedaz-lub-licencjonowanie-genomtec-id-oraz>

4. Changes in the Management Board

On July 31, 2025, Genomtec announced that the Supervisory Board had appointed Leroy Huntley to the Company's Management Board, effective August 1, 2025. Huntley, who has been with Genomtec since 2022, serves as Chief Technology Officer (CTO). His appointment is intended to strengthen the management board's competencies at a crucial time during the ongoing M&A process.

CEO Miron Tokarski emphasized that Huntley's international experience in advising technology companies will be a valuable asset during discussions with potential strategic partners and investors. Leroy Huntley has over 40 years of experience in device design and manufacturing, including nearly 20 years in the medical device sector.

Source: <https://genomtec.com/raporty/#biezaceespi>

5. Patent granted in Japan

On August 1, 2025, Genomtec announced that it has received a patent in Japan for an invention titled "Primer set, reagent composition, and method for detecting atypical bacteria." The patent, number JP 7703649, was issued on June 27, 2025, and its protection will last until October 7, 2041.

The development of this primer set is a key component of the company's LAMP-based diagnostic method. This is the fourteenth patent granted to the company. The management believes that this high level of intellectual property protection will provide the company with an appropriate negotiating position in the commercialization process.

Source: <https://genomtec.com/raporty/#biezaceespi>

6. Audit as part of the ISO 13485 certification

Genomtec has been certified under the ISO 13485 standard since 2021 in the design and development of IVD devices for the detection of pre-defined biological pathogens, which confirms the highest level of quality management systems for medical devices developed by the Company.

The annual audit conducted on August 6, 2025, by TÜV Rheinland confirmed that the quality management system at Genomtec complies with the ISO 13485 standard.

TÜV Rheinland is a leading certification body in the European certification and testing services market. The company is part of the TÜV Rheinland Group, a leading international corporation providing services to industries worldwide.

The ISO 13485 certificate confirms that the quality management systems at Genomtec comply with the highest global standards and confirms the Company's commitment to the safety and quality of manufactured medical devices and guarantees that the Genomtec ID genetic diagnostic system is manufactured with due care and is a completely safe product.

We encourage you to contact the Genomtec SA investor relations team, e-mail: investors@genomtec.com